Press release
Incyte Reports 2024 Third Quarter Financial Results and Provides Updates on Key Clinical Programs
Total revenues of $1,138 million in the third quarter (Q3'24) (+24% Y/Y) Jakafi® (ruxolitinib) net product revenues of $741 million in Q3'24 (+16% Y/Y);
About this update from Incyte Corporation
[{"type":"text","content":"\n\nTotal revenues of $1,138 million in the third quarter (Q3'24) (+24% Y/Y)\n\n\nJakafi® (ruxolitinib) net product revenues of $741 million in Q3'24 (+16% Y/Y); raising full year 2024 Jakafi guidance to a new range of $2,740 - $2,770 million\n\n\nOpzelura® (ruxolitinib) cream net product revenues of $139 million in Q3'24 (+52% Y/Y); launch momentum continues in the U.S. supported by reimbursement expansion in Europe\n\n\nNiktimvo™ (axatilimab-csfr) approved by FDA for the treatment of chronic graft-versus-host disease after failure of at least two prior lines of systemic therapy in adult and pediatric patients\n\n\nRegulatory and development progress with supplemental New Drug Application (sNDA) for ruxolitinib cream in pediatric atopic dermatitis filed and positive data presented for CDK2 inhibitor, retifanlimab and tafasitamab\n\n\nConference Call and Webcast Scheduled Today at 8:00 a.m. ET\n\n WILMINGTON, Del.--(BUSINESS WIRE)--\nIncyte (Nasdaq:INCY) today reports 2024 third quarter financial results, and provides a status update on the Company’s clinical development portfolio.\n\n\"In the third quarter of 2024, we delivered significant achievements, including strong revenue growth for both Jakafi® (ruxolitinib) and Opzelura® (ruxolitinib) cream, and the advancement of our clinical pipeline highlighted by the submission to the FDA of the supplemental New Drug Application (sNDA) for ruxolitinib cream in pediatric atopic dermatitis and several key data readouts including CDK2i, retifanlimab, tafasitamab, povorcitinib and ruxolitinib cream, which all hold near to mid-term launch potential. Additionally, in August, the FDA approved Niktimvo™ (axatilimab-csfr) for patients with chronic graft-versus-host disease, after failure of two prior lines of therapy, making it the first anti-CSF-1R antibody approved to target the inflammation and fibrosis associated with chronic GVHD,\" said Hervé Hoppenot, Chief Executive Officer, Incyte. “We are on track to achieve over ten impactful launches by 2030.”\n\nKey Recent Company Updates\n\n\nIn October, the sNDA submission for ruxolitinib cream in pediatric atopic dermatitis was filed with the FDA with approval anticipated in the second half of 2025.\n\n\nIn October, Opzelura was granted a Notice of Compliance by Health Canada for the topical treatment of both mild to moderate atopic dermatiti...